Gilead Sciences Stock Forecast

Should you buy or avoid in 2025?

February 23, 2025

Early Bird Prime for February 23, 2025 

Despite a rough healthcare market, Gilead Sciences (Nasdaq: GILD) has climbed 51.07% in the last 12 months, including a 19.67% gain in 2025.

Gilead’s secret sauce is its market-leading portfolio of increasingly popular HIV treatments. Their star player, Biktarvy, holds a giant market share in the United States.

It’s no wonder Deutsche Bank upgraded its outlook for Gilead Sciences to Buy from Hold this week. They’re betting on the potential for long-term revenue growth in Gilead's HIV treatment franchise.

But before you start throwing your money at Gilead’s stock, remember that every silver lining has a cloud. Any stock that’s up this much in a volatile field could drop fast.

Gilead is currently wrestling with a decrease in earnings, higher taxes, and pressures from both the government and competitors in 2025.

So, should you invest in Gilead now, or should you avoid the stock if you missed the run-up in the past year? Here’s the answer:

Subscribe to Early Bird Prime to read the rest.

Become a paying subscriber of Early Bird Prime to get access to this post and other subscriber-only content.

Already a paying subscriber? Sign In.

A subscription gets you:

  • • Expert analysis on the best stocks.
  • • Stock price predictions based on machine learning.
  • • Investing picks and recommendations.
  • • Advertisement-free.